Yahoo
NYSEArca - Delayed Quote USD

iShares iBoxx $ High Yield Corporate Bond ETF (HYG)

79.16 -0.05 (-0.06%)
At close: September 4 at 4:00:00 PM EDT
79.21 +0.05 (+0.06%)
After hours: September 4 at 7:58:16 PM EDT
Trade HYG on Coinbase
Chart Range Bar
Loading chart for HYG
  • Previous Close 79.21
  • Open 79.20
  • Bid 79.05 x 8580000
  • Ask 79.16 x 2860000
  • Day's Range 79.15 - 79.24
  • 52 Week Range 78.57 - 81.36
  • Volume 25,119,775
  • Avg. Volume 31,794,423
  • Net Assets 16.19B
  • NAV 79.20
  • PE Ratio (TTM) 10.88
  • Yield 5.88%
  • YTD Daily Total Return 2.24%
  • Beta (5Y Monthly) 0.67
  • Expense Ratio (net) 0.49%

The underlying index is a rules-based index consisting of U.S. dollar-denominated, high yield corporate bonds for sale in the U.S. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index.

iShares

Fund Family

High Yield Bond

Fund Category

16.19B

Net Assets

2007-04-04

Inception Date

Performance Overview

View More

Trailing returns as of 9/3/2026. Category is High Yield Bond.

YTD Return

HYG
2.24%
Category
1.19%

1-Year Return

HYG
4.24%
Category
8.50%

3-Year Return

HYG
8.03%
Category
8.19%

People Also Watch

Holdings

View More

Top 1 Holdings (1.35% of Total Assets)

Symbol Company % Assets
XTSLA 1.35%

Sector Weightings

Research Reports

View More
  • Biogen Is Repositioning Its Portfolio To Partly Offset Ongoing Revenue Declines

    Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

    Rating
    Price Target
  • AI momentum continuing

    Broadcom Inc. is a top five global fabless semiconductor company with leading franchises in wired and wireless communications, enterprise data center and storage, and other end markets. The former Avago acquired Broadcom for $37 billion in 2016 and changed its name to Broadcom Inc. The company has grown via hardware acquisitions, including Agere, LSI Logic, Brocade, and Emulex; and software acquisitions, including CA Inc. in November 2018 and Symantec's enterprise security business in November 2019. Broadcom completed the acquisition of VMware in December 2023.

    Rating
    Price Target
  • Share issuance to fund AI spending

    Alibaba Group Holding Ltd. provides Chinese and international e-commerce platforms, logistics, and ancillary services. The company operates in four segments (Alibaba E-commerce Group, AI Cloud & Compute Services, AI Labs &Applications, and All Others). Key marketplaces include Taobao, a consumer marketplace; Tmall, a third-party platform for brands and retailers; Alibaba.com and 1688.com, online wholesale marketplaces; Alipay, for online payments; and Lazada, for Southeast Asia e-commerce.

    Rating
    Price Target
  • Netflix Earnings: Fine Results but No Excitement, and a Highlighted Metric Again Gets De-Emphasized

    Netflix’s relatively simple business model involves only one business, its streaming service. It has the biggest television entertainment subscriber base in both the United States and the collective international market, with more than 325 million subscribers globally. Netflix has exposure to nearly the entire global population outside of China. The firm has traditionally avoided a regular slate of live programming or sports content, instead focusing on on-demand access to episodic television, movies, and documentaries. The firm introduced ad-supported subscription plans in 2022, giving the firm exposure to the advertising market in addition to the subscription fees that have historically accounted for nearly all its revenue.

    Rating
    Price Target

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: